Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours
- PMID: 30943495
- DOI: 10.1159/000499382
Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours
Abstract
The behaviour of lactotroph tumours varies between benign tumours, those cured by treatment, and that of aggressive tumours, and carcinomas with metastasis. Identification of clinical, pathological and molecular factors is essential for the early identification of patients that may have such aggressive tumours. Plasma prolactin levels and tumour size and invasion, per se, are not prognostic factors. However, tumours appearing at a young age (<20 years), especially in boys, and the presence of genetic predisposition have a poorer prognosis. In addition, lactotroph tumours in men differ from those in women, being larger, more often invasive, and resistant to dopamine agonists. They are also more often high-grade with a high risk of recurrence and malignancy. The expression of estrogen receptor α is lower than in women and is closely correlated to aggressiveness. Proliferation markers (Ki-67 expression: ≥3%, mitotic count n > 2) are correlated to invasion and proliferation, but, taken alone, their prognostic value is debatable. Based on a 5-tiered clinicopathological classification, and taking into account invasion and proliferation, a grade 2b (aggressive) lactotroph tumour has a 20× risk of progression compared to a grade 1a (benign) tumour. Moreover, lactotroph tumours are the second-most frequent aggressive and malignant tumour. Other factors, such as the expression of growth factors (vascular endothelial growth factor [VEGF] and epidermal growth factor [EGF]), the genes regulating invasion, differentiation and proliferation, adhesion molecules (E-cadherin), matrix metalloproteinase 9, and chromosome abnormalities (chromosomes 11, 19, and 1), have also been correlated with aggressiveness. Currently, clinical signs, a prognostic classification, and molecular and genetic markers may all help the clinician in the early identification of aggressive lactotroph tumours and enable stratification of their management.
Keywords: Aggressive tumours; Lactotroph tumour; Pituitary tumour; Prognostic factors; Prolactinoma; Sex.
© 2019 S. Karger AG, Basel.
Similar articles
-
Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.Acta Neurochir (Wien). 2005 Jul;147(7):751-7; discussion 757-8. doi: 10.1007/s00701-005-0498-2. Epub 2005 Mar 14. Acta Neurochir (Wien). 2005. PMID: 15971099
-
A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.Endocr Relat Cancer. 2007 Sep;14(3):887-900. doi: 10.1677/ERC-07-0062. Endocr Relat Cancer. 2007. PMID: 17914117
-
Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.Eur J Endocrinol. 2014 Mar 13;170(4):R121-32. doi: 10.1530/EJE-13-1031. Print 2014 Apr. Eur J Endocrinol. 2014. PMID: 24431196 Review.
-
Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours.Eur J Endocrinol. 2023 Sep 1;189(3):372-378. doi: 10.1093/ejendo/lvad114. Eur J Endocrinol. 2023. PMID: 37721395
-
Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications.Int J Mol Sci. 2021 Oct 18;22(20):11247. doi: 10.3390/ijms222011247. Int J Mol Sci. 2021. PMID: 34681905 Free PMC article. Review.
Cited by
-
Aggressive prolactinomas: how to manage?Pituitary. 2020 Feb;23(1):70-77. doi: 10.1007/s11102-019-01000-7. Pituitary. 2020. PMID: 31617128 Review.
-
Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent.Eur J Med Res. 2023 Aug 25;28(1):297. doi: 10.1186/s40001-023-01271-8. Eur J Med Res. 2023. PMID: 37626424 Free PMC article. Review.
-
Approach to the Patient With Prolactinoma.J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-2423. doi: 10.1210/clinem/dgad174. J Clin Endocrinol Metab. 2023. PMID: 36974474 Free PMC article. Review.
-
Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study.Front Endocrinol (Lausanne). 2021 Jul 12;12:684055. doi: 10.3389/fendo.2021.684055. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34322092 Free PMC article.
-
Fluorescence detection of pituitary neuroendocrine tumour during endoscopic transsphenoidal surgery using bevacizumab-800CW: a non-randomised, non-blinded, single centre feasibility and dose finding trial [DEPARTURE trial].Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):660-668. doi: 10.1007/s00259-024-06947-9. Epub 2024 Oct 11. Eur J Nucl Med Mol Imaging. 2025. PMID: 39390132 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical